Acute Lymphoblastic Leukemia in Adults

Our pathologists, hematologists, and oncologists combine their expertise to determine the genetic characteristics of acute lymphoblastic leukemia, a fast-growing cancer of the blood and bone marrow. Together, we accurately diagnose the condition and create a personalized treatment plan, which may include chemotherapy, targeted medications, or stem cell transplantation. Throughout the treatment process and beyond, we provide supportive services to you and your loved ones.

Clinical Trials and Research Studies

Phase 1

A Phase 1 Study Evaluating Safety Tolerability and Pharmacokinetics of Escalating Doses of AGS62P1 Given as Monotherapy in Subjects with Acute Myeloid Leukemia (AML)

Phase 2

AALL1521: INCB 18424-269 A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia (ALL)

Phase 3

AALL1331; Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467 NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Phase 3

Treatment Of Patients Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) Or Localized B-Lineage Lymphoblastic Lymphoma